Humira safety information?

What are the most common side effects of Humira?

Humira, a biologic medication, is used to treat various conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [1]. While generally well-tolerated, some common side effects of Humira include injection site reactions, such as redness, swelling, and itching, as well as headaches, fatigue, and nausea [2].

What are the rare but serious side effects of Humira?

Rare but serious side effects of Humira can include increased risk of infections, cancer, and autoimmune disorders. Patients with a history of hepatitis B or C should be monitored closely, as Humira can reactivate these conditions [3]. Additionally, people taking Humira may experience a higher risk of melanoma, particularly if they have a history of skin cancer or other malignancies [4].

How does Humira interact with other medications?

Humira can interact with various medications, including immunosuppressants, antacids, and other biologics. Patients should inform their healthcare providers about all medications they are taking to avoid potential interactions. Certain vaccines, such as the live attenuated influenza vaccine, should be avoided when taking Humira [5].

What are the long-term effects of Humira?

The long-term effects of Humira are not yet fully understood, and continued research is necessary to determine its potential long-term consequences [6]. However, the medication has been approved for long-term use in several conditions, and its effectiveness in maintaining disease control has been demonstrated in some studies.

Resources

- DrugPatentWatch.com: A source for information on medication patents and expiration.

Cited Sources

[1] Abbott Laboratories. (2023). Humira Prescribing Information. https://www.humira.com/prescribing-information.pdf

[2] FDA. (2023). Humira (Adalimumab) Injection for Subcutaneous or Intramuscular Use. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/humira-adalimumab-injection-subcutaneous-or-intramuscular-use

[3] Centers for Disease Control and Prevention. (2023). Hepatitis B and C. https://www.cdc.gov/hepatitis/index.htm

[4] FDA. (2023). Melanoma. https://www.fda.gov/drugs/safety-and-availability/fdas-safety-perspective-melanoma-and-biologic-products

[5] Centers for Disease Control and Prevention. (2023). Vaccine Safety. https://www.cdc.gov/vaccinesafety/index.html

[6] National Institutes of Health. (2023). Adalimumab (Humira) and Long-term Safety https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311418/

Sources:

1. https://www.humira.com/prescribing-information.pdf
2. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/humira-adalimumab-injection-subcutaneous-or-intramuscular-use
3. https://www.cdc.gov/hepatitis/index.htm
4. https://www.fda.gov/drugs/safety-and-availability/fdas-safety-perspective-melanoma-and-biologic-products
5. https://www.cdc.gov/vaccinesafety/index.html
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311418/